S.V.Biovac Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 31 Year, 13 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -52.31%
- Profit Growth 23.81%
- Ebitda -26.98%
- Net Worth -18.44%
- Total Assets 30.84%
About S.V.Biovac Pharmaceuticals
S.V.Biovac Pharmaceuticals Pvt Ltd (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 January 1994 and has a history of 31 years. Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hitesh Kumbhare, Bharti Kumbhare, and Vijay Athwal serve as directors at the Company.
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24232MP1994PTC008065
- Company No.
008065
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jan 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at S.V.Biovac Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hitesh Kumbhare  | Director | 23-Jan-2020 | Current |
| Bharti Kumbhare | Director | 23-Jan-2020 | Current |
| Vijay Athwal | Director | 23-Jan-2020 | Current |
Financial Performance of S.V.Biovac Pharmaceuticals.
S.V.Biovac Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced significant reduction in revenue, with a 52.31% decrease. The company also saw a substantial improvement in profitability, with a 23.81% increase in profit. The company's net worth observed a substantial decline by a decrease of 18.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S.V.Biovac Pharmaceuticals?
In 2017, S.V.Biovac Pharmaceuticals had a promoter holding of 99.60% and a public holding of 0.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Healpros Biomedicals Private LimitedHitesh Kumbhare is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at S.V.Biovac Pharmaceuticals?
S.V.Biovac Pharmaceuticals has a workforce of 1 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S.V.Biovac Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S.V.Biovac Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
